Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05362760
Title Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management (MINERVA)
Recruitment Recruiting
Gender female
Phase FDA approved
Variant Requirements No
Sponsors Prof. W. Janni

Her2-receptor negative breast cancer


Abemaciclib + Exemestane

Abemaciclib + Fulvestrant

Abemaciclib + Letrozole

Abemaciclib + Anastrozole

Age Groups: adult | senior
Covered Countries DEU

No variant requirements are available.